Apogee Therapeutics 株価情報 (NASDAQ: APGE)

最新ニュース Apogee Therapeutics (NASDAQ:APGE) 株価情報

APOGEE THERAPEUTICS INC

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics Inc

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Hold and lowers the price target from $1.25 to $1.

News

Price Target

Analyst Ratings

BOLT

Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1

UBS analyst Brent Dilts maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Buy and lowers the price target from $64 to $62.

UBS Maintains Buy on Realty Income, Lowers Price Target to $62

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading higher Tuesday. The stock may be moving on continued momentum after the U.S. and China on Monday agreed to a reduction in most tariffs <a href="https://www.benzinga.com//node/45352452">on each other&#8217;s goods.</a>
What To Know: The deal will lower U.S. tariffs on Chinese imports from 145% to 30% and Chinese levies on U.S. goods from 125% to 10% for a three-month period.
The revised U.S. tariffs consist of a 10% base rate on all imports, plus an additional 20% tariff implemented earlier this year by President Donald Trump in response to claims that China is manufacturing chemicals associated with fentanyl.
On the U.S. side, the talks were led by Trade Representative&nbsp;Jamieson Greer&nbsp;and Treasury Secretary&nbsp;Scott Bessent, while Vice Premier&nbsp;He Lifeng&nbsp;led the discussions for China.
Bessent said at a news conference that, "We concluded that we have shared interests, and we both have an interest in balanced trade."&nbsp;
What Else: NVIDIA announced a strategic partnership with HUMAIN on Tuesday aimed at establishing Saudi Arabia as a leader in artificial intelligence (AI) and GPU cloud computing. 
As part of its plan to build AI factories in Saudi Arabia, HUMAIN will deploy an 18,000-unit NVIDIA GB300 Grace Blackwell AI supercomputer powered by NVIDIA InfiniBand networking.
HUMAIN also plans to use the NVIDIA Omniverse platform as a multi-tenant system to support development in AI and robotics.
Nvidia is also set to report first-quarter earnings on May 28 after the market closes. Analysts estimate earnings per share of 89 cents and revenue of $43.07 billion, per data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
See Also: <a href="https://www.benzinga.com/insights/short-sellers/25/05/45377227/is-cheesecake-factory-gaining-or-losing-market-support">Is Cheesecake Factory Gaining or Losing Market Support?</a>
NVDA Price Action: At the time of writing, NVIDIA stock is trading 5.56% higher at $129.84, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

Movers

NVDA

What's Going On With NVIDIA Stock Tuesday?

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a href="https://www.benzinga.com/pressreleases/25/05/g45374688/amd-unveils-epyc-4005-series-processors-delivering-workload-optimized-solutions-for-entry-level-en" target="_blank" rel="noreferrer noopener">announced the launch</a> of AMD EPYC 4005 Series processors on Tuesday.
These purpose-built processors enable right-sized solutions with enterprise-class features and leadership performance for small and medium businesses and hosted IT service providers.
AMD EPYC 4005 Series CPUs deliver the performance, features, and efficiency growing businesses need to power everything from enterprise applications and virtualized environments to dedicated, all-day hosted services in the cloud.
Also Read: <a href="https://www.benzinga.com/25/05/45260942/amd-shifts-chip-orders-to-taiwan-semiconductor-dropping-samsung-in-big-manufacturing-move" target="_blank" rel="noreferrer noopener">Advanced Micro Devices Drops Samsung, Shifts Chip Orders To Taiwan Semiconductor</a>
Utilizing the AM5 socket used for the AMD EPYC 4004 Series CPUs, the EPYC 4005 Series delivers an innovative compute solution for a broad set of enterprise-class form factors like servers, blades, and towers.
AMD EPYC 4005 Series processors enable various broadly deployed enterprise solutions.
Leading partners and customers support them, including Altos, ASRock Rack, Gigabyte, Lenovo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNVGY#OTC">LNVGY</a>), and Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
AMD stock plunged over 27% in the last 12 months amid intense rivalry with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for GPU market share.
AMD reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45237261/amd-q1-earnings-revenue-eps-beat-driven-by-expanding-data-center-ai-momentum-chipmaker-expects-strong-growth-in-2025" rel="noreferrer noopener">first-quarter revenue</a> of $7.44 billion, up 36%, beating&nbsp;analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share.
AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion.
Wall Street analyst <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45264199/amd-market-position-is-the-best-in-the-companys-history-says-analyst" target="_blank" rel="noreferrer noopener">highlighted the company&#8217;s</a> gross margin expansion to 54%, expecting strong sequential growth in the Client and Gaming segments. BofA Securities analyst Vivek Arya highlighted &#8220;multiple growth cylinders&#8221; and continued market share gains in PC/server CPU against Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). 
Price Action: AMD stock is trading up 3.34% to $111.73 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45291509/nvidia-broadcom-amd-surge-as-trump-reshapes-ai-chip-export-rules-to-ease-market-pressure" target="_blank" rel="noreferrer noopener">Nvidia, Broadcom, AMD Gain As Trump Reshapes AI Chip Export Rules To Ease Market Pressure</a></li>
</ul>
Image by sdx15 via Shutterstock

Tech

INTC

LNVGY

SMCI

AMD Launches EPYC 4005 Chips For Small Business And Cloud

Truist Securities analyst Jennifer Demba initiates coverage on Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Hold rating and announces Price Target of $52.

Initiation

ZION

Truist Securities Initiates Coverage On Zions Bancorp with Hold Rating, Announces Price Target of $52

WIIM

Super Micro Computer shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $41 price target.

Truist Securities analyst Brandon King initiates coverage on East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) with a Hold rating and announces Price Target of $102.

EWBC

Truist Securities Initiates Coverage On East West Bancorp with Hold Rating, Announces Price Target of $102

UBS analyst A.J. Rice maintains AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) with a Neutral and lowers the price target from $30 to $25.5.

UBS Maintains Neutral on AMN Healthcare Services, Lowers Price Target to $25.5

Truist Securities analyst Brandon King initiates coverage on Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Buy rating and announces Price Target of $92.

Truist Securities Initiates Coverage On Western Alliance with Buy Rating, Announces Price Target of $92

Best known <a href="https://www.benzinga.com/general/gaming/23/01/30412695/gamestop-short-squeeze-anniversary-a-look-back-at-david-vs-goliath-battle-and-whats-next">for shorting stocks</a> like GameStop, Citron Research's Andrew Left also shares long calls on stocks that are undervalued by Wall Street.
Citron shared its latest stock pick Tuesday, a company it believes is misunderstood by investors.
What Happened: Citron said Tuesday it is "pounding the table" on Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), a company best known for its mortgage and personal finance businesses. Citron said <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44565671/rocket-acquires-mr-cooper-just-weeks-after-buying-redfin-brings-together-the-homeownership-experience-at-scale">recent acquisitions by the company</a> could also help the bullish case.
"This will be our call of the year!" Citron <a href="https://x.com/CitronResearch/status/1922295155253821907">tweeted</a>.
Citron said Rocket Companies is a "sleeping juggernaut of real estate" with vertical integration. The tweet said the company is leveraging AI and data to "build the Amazon of Housing."
Rocket is more than a play on mortgage refinances and doesn't need lower interest rates to win, the tweet said.
"Rocket is building the dominant real estate platform – where higher rates weed out competition and drive more share to scale players."
Citron said the U.S. mortgage market is still behind with less than 15% of mortgages originating online, despite 85% of home searches starting online.
AI could be Rocket's biggest advantage with the company building proprietary, in-house AI, according to Citron.
"Rocket Logic is quietly becoming the brain of the entire platform. This is Salesforce meets Zillow meets TurboTax, but for mortgages."
The tweet says Rocket is using AI in a boring sector, likely hurting its valuation.
"Rocket is quietly using AI to modernize the most broken part of consumer finance: housing."
Read Also: <a href="https://www.benzinga.com/25/04/44942759/gamestop-short-seller-andrew-left-goes-long-on-china-and-these-two-us-stocks-amid-the-market-correction-heres-more-on-it">GameStop Short Seller Andrew Left Goes Long On China And These 2 US Stocks Amid Market Correction</a>
What's Next: Citron said Rocket's recent acquisition of Mr. Cooper was underappreciated and creates a 1+1=3 scenario. The acquisition adds scale, reach, leads and margin expansion according to Citron Research.
The tweet lays out Rocket Companies&#8217; future valuation in the first refinance boom. The company gained EBITDA and scale from the acquisitions of Mr. Cooper and Redfin. Citron predicts Rocket Companies could have $4 billion of annual EBITDA in the future.
With a 15x multiple on EBITDA, an enterprise value of $60 billion is reached, which would make Rocket Companies stock worth around $33.33.
"Rocket Mortgage is on track to become the most dominant mortgage company in the world within three years. The U.S. residential housing market is the largest commerce vertical on the planet – bigger than autos, bigger than health care – and it's still largely analog, fragmented, and inefficient."
RKT Price Action: Rocket Companies stock is up 4.1% to $12.14 on Tuesday versus a 52-week trading range of $10.06 to $21.38. Rocket Companies stock is up 12.1% year-to-date in 2025, while shares remain down over 15% in the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/01/43258090/gamestop-short-seller-wants-freedom-of-speech-for-millions-having-stock-market-conversations-questioning-sec-on-what-protects-honest-opinions">Gamestop Short Seller Wants Freedom Of Speech For &#8216;Millions&#8217; Having Stock Market Conversations, Questioning SEC On &#8216;What Protects Honest Opinions?&#8217;</a></li>
</ul>
Photo: bilanol/shutterstock

Trading Ideas

Real Estate

Rocket Companies Is Citron's 'Call of the Year,' Dubbed The 'Amazon Of Housing'

Truist Securities analyst John McDonald initiates coverage on First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Hold rating and announces Price Target of $21.

Truist Securities Initiates Coverage On First Horizon with Hold Rating, Announces Price Target of $21

Shareholders Must Hold Shares in Multiples of Eight by Market Close on May 27, 2025 to Avoid Fractional Share Cash-Out
LUXEMBOURG, May 13, 2025 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. ("Altisource" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>), a leading provider and marketplace for the real estate and mortgage industries, today announced that its shareholders have overwhelmingly approved a reverse stock split (the "Share Consolidation") at the Company's Extraordinary General Meeting of Shareholders held on May 13, 2025.
Pursuant to the Share Consolidation, every eight (8) shares of the Company's common stock will be consolidated into one (1) share of common stock, reducing the total number of outstanding shares from 88,951,925 to approximately 11,118,990. The Share Consolidation is scheduled to become effective on May 28, 2025, subject to the completion of required administrative procedures.

ASPS

Altisource Shareholders Approve 1-For-8 Reverse Stock Split And Treatment Of Fractional Shares

UBS analyst Michael Goldsmith maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Buy and lowers the price target from $86 to $84.

UBS Maintains Buy on Agree Realty, Lowers Price Target to $84

Truist Securities analyst Brandon King initiates coverage on SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) with a Buy rating and announces Price Target of $106.

Truist Securities Initiates Coverage On SouthState with Buy Rating, Announces Price Target of $106

Truist Securities analyst David Smith initiates coverage on Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Buy rating and announces Price Target of $56.

Truist Securities Initiates Coverage On Synovus Financial with Buy Rating, Announces Price Target of $56

Truist Securities analyst Brandon King initiates coverage on Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Buy rating and announces Price Target of $123.

PNFP

Truist Securities Initiates Coverage On Pinnacle Finl Partners with Buy Rating, Announces Price Target of $123

Truist Securities analyst David Smith initiates coverage on Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Buy rating and announces Price Target of $61.

Truist Securities Initiates Coverage On Webster Financial with Buy Rating, Announces Price Target of $61

UBS analyst Michael Goldsmith maintains Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Neutral and lowers the price target from $18 to $17.

UBS Maintains Neutral on Broadstone Net Lease, Lowers Price Target to $17

Truist Securities analyst David Smith initiates coverage on Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) with a Hold rating and announces Price Target of $26.

Truist Securities Initiates Coverage On Associated Banc with Hold Rating, Announces Price Target of $26

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 3.04% on an annualized basis producing an average annual return of 14.74%. Currently, Analog Devices has a market capitalization of $112.26 billion. 
Buying $1000 In ADI: If an investor had bought $1000 of ADI stock 15 years ago, it would be worth $8,201.09 today based on a price of $226.35 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747152922_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Press Releases

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Earnings

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Health Care

General

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Comments

Apogee Therapeutics

ニュース

最新ニュース Apogee Therapeutics (NASDAQ:APGE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル